[Non-small cell lung cancer: Perioperative treatments]
| Autor: | Westeel , Virginie, Schipman , Benjamin, Jacoulet , Pascale |
|---|---|
| Přispěvatelé: | Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ) -Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) |
| Jazyk: | francouzština |
| Rok vydání: | 2011 |
| Předmět: |
MESH: Combined Modality Therapy
Lung Neoplasms MESH: Radiotherapy Adjuvant MESH: Neoadjuvant Therapy Antineoplastic Agents [SDV.CAN]Life Sciences [q-bio]/Cancer MESH : Radiotherapy Adjuvant [ SDV.CAN ] Life Sciences [q-bio]/Cancer MESH: Patient Care Team Carcinoma Non-Small-Cell Lung MESH: Cooperative Behavior Humans MESH : Neoplasm Staging MESH : Lung Neoplasms Cooperative Behavior Neoplasm Staging Patient Care Team MESH : Carcinoma Non-Small-Cell Lung MESH: Humans MESH : Neoplasm Recurrence Local MESH : Patient Care Team MESH : Humans MESH : Chemotherapy Adjuvant MESH: Neoplasm Staging MESH : Cooperative Behavior Combined Modality Therapy MESH : Interdisciplinary Communication Neoadjuvant Therapy MESH: Lung Neoplasms MESH : Antineoplastic Agents Chemotherapy Adjuvant MESH: Chemotherapy Adjuvant MESH: Antineoplastic Agents Interdisciplinary Communication Radiotherapy Adjuvant MESH: Interdisciplinary Communication Neoplasm Recurrence Local MESH : Combined Modality Therapy MESH : Neoadjuvant Therapy MESH: Neoplasm Recurrence Local MESH: Carcinoma Non-Small-Cell Lung |
| Zdroj: | La Presse medicale La Presse medicale, Paris, Masson et Cie, 2011, 40 (4 Pt 1), pp.398-403. ⟨10.1016/j.lpm.2011.02.006⟩ La Presse medicale, Paris, Masson et Cie, 2011, 40 (4 Pt 1), pp.398-403. 〈10.1016/j.lpm.2011.02.006〉 |
| ISSN: | 0032-7867 |
| DOI: | 10.1016/j.lpm.2011.02.006⟩ |
| Popis: | International audience; The objectives of perioperative treatments in non-small cell lung cancer (NSCLC) are to reduce the risk of recurrence, by the early destruction of micrometastases. Data from the literature have been used to precise their indications and modalities. However, for each patient, the decision of a perioperative treatment must result from a multidisciplinary discussion. Perioperative chemotherapy is indicated in stage II or III NSCLC. Adjuvant chemotherapy, which has a highest best level of evidence, is standard, with a 5% survival benefit at 5 years. Preoperative chemotherapy is an option. Postoperative mediastinal radiotherapy has to be discussed in pN2 disease. Ongoing studies in the perioperative setting evaluate the role of targeted agents, and the interest of personalized strategies based on biological markers. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|